The U.S. Food and Drug Administration approved Jideytro (zidesamtinib) on July 22, 2026, for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have already received at least one prior ROS1 kinase inhibitor. The approval was announced by GlaxoSmithKline and arrived nearly two months ahead of the drug's original target action date of September 18, 2026, a timing that reflects the strength of the supporting evidence and the FDA's Breakthrough Therapy and Orphan Drug designations granted to zidesamtinib during its development.
This marks GSK's first approved medicine in lung cancer. The drug was developed by Nuvalent, which GSK acquired for $10.6 billion in June 2026.
Why This Matters
Lung cancer kills more Americans each year than any other cancer, and non-small cell lung cancer accounts for roughly 85 percent of all lung cancer cases. Within NSCLC, molecular testing has progressively identified genomic subtypes that respond to targeted therapies. ROS1-positive NSCLC is one of those subtypes, representing approximately 1 to 2 percent of all NSCLC diagnoses globally, which translates to approximately 50,000 new diagnoses worldwide annually, according to GSK's approval announcement.
What makes ROS1-positive NSCLC clinically distinctive is who it tends to affect. The mutation frequently appears in patients in their 40s and 50s with little to no smoking history, a profile sharply different from the typical lung cancer patient. For this group, effective second- and third-line treatment options after initial ROS1 inhibitor therapy have failed have been limited. Jideytro is designed to directly address that gap.
What We Know So Far
Jideytro is a next-generation ROS1-selective kinase inhibitor. Its mechanism targets the ROS1 fusion protein, a driver mutation that causes uncontrolled cell growth in the affected subset of lung cancers. What distinguishes it from first-generation ROS1 inhibitors such as crizotinib and entrectinib is its design to overcome resistance mutations that develop after treatment with those earlier drugs, and its ability to penetrate the blood-brain barrier to address cancer that has spread to the brain.
The FDA approval is based on results from 117 patients with ROS1-positive NSCLC who had previously received a ROS1 inhibitor in the global, single-arm Phase 1/2 ARROS-1 trial. In that population, the overall response rate was 44 percent. Among those who responded, 82 percent maintained their response at six months and 69 percent at 12 months. In the most heavily pretreated subgroup, patients who had received two or more prior targeted therapies plus chemotherapy, the response rate was 38 percent, indicating meaningful activity even in patients with very limited remaining options.
Where the Impact Is Highest
Patients at major lung cancer centers in metropolitan areas including New York's Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center in Houston, UCLA's Jonsson Comprehensive Cancer Center in Los Angeles, and the University of Chicago Medicine are most likely to have access to molecular testing that identifies ROS1 status and to oncologists experienced with second-line targeted therapy for this subtype.
Because ROS1-positive NSCLC affects a younger population than most lung cancer subtypes, patients in their 40s presenting with unexplained respiratory symptoms, particularly non-smokers, should discuss molecular testing with their oncologist. The genomic profile that determines ROS1 status must be established before a patient can be considered for zidesamtinib, and testing should be requested at the time of initial diagnosis in all NSCLC patients.
What Doctors and Experts Say
Alexander Drilon, MD, an oncologist at Memorial Sloan Kettering Cancer Center and an ARROS-1 investigator, said at the time of approval that despite prior advances in treatment, resistance mutations, disease progression in the brain, and treatment-related adverse events continue to create challenges for patients. "The responses observed in ARROS-1, including in heavily pretreated patients, represent meaningful progress for people living with this disease," Drilon said.
Oncology Nursing News noted that the approval arrived ahead of schedule, having received both Breakthrough Therapy and Orphan Drug designations from the FDA during development. The Breakthrough Therapy designation is reserved for drugs that show substantial improvement over existing therapies on at least one clinically significant endpoint. GSK stated that zidesamtinib was designed to combine high target selectivity, broad coverage of resistance mutations, and blood-brain barrier penetration to address disease progression in the brain.
What the Evidence Shows and What It Does Not
The approval is based on a single-arm Phase 1/2 trial of 117 patients who had previously received a ROS1 kinase inhibitor. Single-arm trials do not include a comparator group, meaning the 44 percent response rate reflects activity against the drug's targets but is not directly measured against another active treatment in a randomized controlled trial. This is standard practice in oncology for genomically defined populations where randomized comparison would be ethically and logistically challenging. The FDA's accelerated review reflects this pragmatic approach to rare molecular subtypes.
Adverse reactions in the pooled safety population of 446 patients included edema, peripheral neuropathy, constipation, fatigue, and dyspnea, all of which are manageable but require clinical monitoring and supportive care, according to Medscape's approval coverage. The prescribing information, available at fda.gov, provides full safety and dosing details.
MedicalDaily Evidence Check
The ARROS-1 trial is a global, single-arm Phase 1/2 study that enrolled 117 patients with previously treated ROS1-positive NSCLC, with key efficacy data presented at the 2025 World Conference on Lung Cancer. The study found a 44 percent overall response rate, with 82 percent of responding patients maintaining their response at six months and 69 percent at twelve months.
Because ARROS-1 is a single-arm trial without a randomized comparator group, the data show anti-tumor activity but do not prove that zidesamtinib is superior to any other active treatment in a head-to-head trial setting. Readers should know that this drug is specifically for adult patients who have already received at least one prior ROS1 kinase inhibitor and whose cancer has been confirmed as ROS1-positive through molecular testing, and it is not a first-line option.
Who Faces the Greatest Risk Without This Option
ROS1-positive NSCLC patients who have progressed on first-line crizotinib, entrectinib, lorlatinib, or other ROS1-directed therapies and who have developed resistance mutations are the population for whom Jideytro was specifically designed. Patients whose cancer has spread to the brain have historically had particularly limited second-line options, given that many prior agents do not penetrate the blood-brain barrier effectively.
The 50,000 annual worldwide diagnoses of ROS1-positive NSCLC include patients across all racial and ethnic backgrounds, with some research suggesting the mutation may be slightly more prevalent in women and in individuals of East Asian descent, although the molecular driver transcends demographic categories.
Symptoms and Warning Signs to Watch For
Lung cancer symptoms include a persistent new cough or a change in a chronic cough, coughing up blood, chest pain that worsens with deep breathing or laughing, hoarseness, loss of appetite, unexplained weight loss, shortness of breath, feeling tired or weak, and new onset of wheezing. Symptoms from lung cancer that has spread to the brain can include headaches, seizures, dizziness, or vision changes.
Non-smoking adults in their 40s who develop any of these symptoms, particularly respiratory symptoms that persist for more than two to three weeks without an obvious cause, should seek prompt medical evaluation and specifically request that their clinician consider whether molecular testing is appropriate.
What You Can Do Now
Patients with a recent NSCLC diagnosis should ask their oncologist whether molecular profiling of the tumor has been performed, and if so, whether results have been reviewed for ROS1 rearrangement, EGFR mutation, ALK rearrangement, and other actionable drivers. Patients who know their cancer is ROS1-positive and whose disease has progressed on a first-line ROS1 inhibitor should ask about Jideytro as a treatment option and review eligibility criteria with their oncologist.
For families of patients with lung cancer who have never smoked, the conversation about comprehensive molecular testing is especially important, as non-smokers are disproportionately likely to harbor actionable driver mutations including ROS1.
Cost and Access: What Patients Should Know
As a newly approved branded specialty drug, Jideytro will carry a significant price, likely in line with other targeted oncology therapies, which commonly cost $10,000 to $20,000 or more per month before insurance. Commercial insurance and Medicare Part D plans that cover targeted NSCLC therapies are the primary access pathway. GSK typically offers patient assistance programs at launch. Patients facing coverage challenges should contact their cancer center's social worker or financial navigator, and can also contact the Patient Advocate Foundation or NeedyMeds for guidance on access programs.
What Happens Next
GSK is advancing additional Nuvalent-derived lung cancer drugs through the pipeline, including neladalkib (NVL-655) for ALK-altered NSCLC, currently under FDA review with a target decision date of November 27, 2026. Investigators are also studying zidesamtinib as a first-line treatment in treatment-naive ROS1-positive patients in the ongoing ARROS-1 trial expansion. Full prescribing information is available on the FDA website.
The Bottom Line
The FDA's approval of Jideytro on July 22, 2026, gives oncologists a new targeted option for one of the most difficult-to-treat situations in ROS1-positive lung cancer: disease that has progressed after first-line targeted therapy. For younger non-smoking patients whose cancer has become resistant to prior ROS1 inhibitors or has spread to the brain, this approval represents a meaningful new clinical pathway. The most important immediate action for eligible patients is confirming their molecular profile with their oncologist and discussing whether Jideytro fits their current treatment situation.
.png?w=600)
